FINWIRES · TerminalLIVE
FINWIRES

Clinuvel Unlikely to Seek Scenesse's Vitiligo Approval Before Phase 3 Completion, Says Jefferies

By

Clinuvel Pharmaceuticals (ASX:CUV) is unlikely to seek regulatory approval for Scenesse in vitiligo until the Phase 3 CUV105 and CUV107 clinical trials are completed, according to a Friday Jefferies note.

The company said on Friday that the European Medicines Agency (EMA) has proposed evaluating the company's Scenesse drug for the treatment of systemic vitiligo based on a "totality of evidence" regulatory approach.

Jefferies said that the EMA's decision is a positive for the company because of the high unmet medical need for Vitiligo treatment.

The investment firm has pushed back its revenue expectations from Scenesse in vitiligo, which is now expected to begin in the second half of fiscal 2029 rather than fiscal 2028.

Jefferies kept a buy rating on Clinuvel and cut its price target to AU$39.20 from AU$40.50.

Related Articles

Asia

Chifeng Jilong's Q1 Profit Soars 104%

Chifeng Jilong Gold Mining (SHA:600988, HKG:6693) recorded a 104% rise in attributable profit in the first quarter of 2025 to 988.2 million yuan from 483.4 million yuan in the year-ago period, according to a Friday Hong Kong bourse filing.The miner's earnings per share jumped to 0.52 yuan from 0.29 yuan in the corresponding period of the previous fiscal year.Operating income increased 48% to 3.55 billion yuan from 2.41 billion yuan a year prior.The firm attributed the positive performance to the optimization of production organization and operational management, allowing the firm to benefit from a year-over-year rise in goldselling price.

HKG:6693SHA:600988
Asia

Jiayuan Services Raises HK$14.6 Million from Share Placement

Jiayuan Services (HKG:1153) completed the placing of 60.5 million shares to two investors at HK$0.25 apiece to raise net proceeds of HK$14.6 million, according to a Friday Hong Kong bourse filing.The shares represent approximately 9% of the real estate developer's enlarged issued share capital.The firm will use proceeds for general working capital, as well as for the settlement of outstanding payables.

HKG:1153
Asia

BOCOM International Unit Buys $9 Million Bonds by Sumitomo Mitsui Trust Bank

BOCOM International (HKG:3329) unit Preferred Investment Management acquired $9 million of certain bonds for $9.1 million from the over-the-counter market on Wednesday, according to a Friday Hong Kong bourse filing.The bonds will be issued by Sumitomo Mitsui Trust Bank and listed on the Singapore Exchange.The company purchased the bonds for investment purposes.

HKG:3329